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from remission, progression to long-term adverse outcomes (cirrhosis, decompen-
sated cirrhosis, hepatocellular carcinoma, end-stage liver disease) and commonly 
observed side effects (anemia, neutropenia and rash) along with a gradient of their 
severity. Model inputs were determined from a review of the published literature 
and phase II or III clinical trials. Clinical trials estimates were converted to risk ratios 
to facilitate comparison. Costs were inflated to 2013 US dollars. Costs and quality 
adjusted life years were discounted at standard rate of 5%. Sensitivity analyses 
were performed to assess model sensitivity and address uncertainty. Results: 
Relative to treatment with PR only, response-guided triple therapy with BOC+PR 
was the most cost effective therapy (ICER $28,723/QALY) followed by response-
guided triple therapy with TVR+PR (ICER $64,569/QALY). PR treatments with SIM or 
SOF were dominated by BOC+PR. The model was sensitive to variations in costs of 
initial drug therapy and likelihood of attaining SVR. ConClusions: Addition of 
protease inhibitors to PR therapy improves health outcomes. Response-guided regi-
men BOC+PR was found to be cost-effective for treating newly diagnosed genotype 
1 HCV patients. Shortening of PR therapy guided by a rapid virologic response may 
help reduce overall costs. Robust sensitivity analyses can help in overcoming the 
challenge of sparse data availability.
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objeCtives: To compare Ertapenem with piperacillin/tazobactam (pip/tazo) for the 
treatment of moderate to severe community acquired intra-abdominal infections 
(c-IAI) in Colombia health care setting, with respect to cost and outcomes taking 
into account development of anti-microbial resistance (AMR). Methods: A previ-
ously published decision tree model was adapted to estimate cost-effectiveness 
of Ertapenem vs. pip/tazo. Clinical efficacy, adverse events and medical resource 
use were derived from literature. AMR to Ertapenem and pip/tazo was calculated 
as weighted average based on the % distribution of different pathogens in c-IAI in 
Colombia and the sensitivity of Erta vs. pip/tazo for each pathogen from Colombia 
SMART data. The resistance-adjusted effectiveness is then computed based on effi-
cacy from clinical trial and local AMR data, Model outcomes included resistance, 
clinical success, deaths, life years, direct costs, and costs per successfully treated 
patient. Results: The overall resistance of Ertapenem vs. pip/tazo for c-IAI is 21.4% 
vs. 43.4%. The resistance-adjusted effectiveness are 70.3% vs. 46% for Ertapenem vs. 
pip/tazo. Daily drug costs are 133,550 (Ertapenem) vs. 34,989 (pip/tazo) Colombian 
Pesos. Total costs (including drug costs, hospitalization, cost of 2nd-line treatment 
& cost of AEs) are 7,162,081 (Ertapenem) vs. 7,230,902 (pip/tazo) Pesos. During the 
first hospitalization period, Ertapenem is associated with a 24.3% higher treatment 
success rate, and a 68,821 Pesos in cost saving when compared with Pip/tazo. The 
Incremental cost per successfully treated patient (ICER) is -283,405 Colombian Pesos 
($145.39 USD) for Ertapenem vs. Pip/tazo. ConClusions: Accounting for local anti-
microbial resistance, Ertapenem is more effective and cost-saving vs. pip/tazo for 
the treatment of moderate to severe community acquired intra-abdominal infec-
tions in Colombia.
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objeCtives: Pneumococcal diseases and influenza have caused substantial clini-
cal and economic burden in Taiwan especially in high-risk groups such as infants 
and elderly. It has been shown that influenza can increase the risk of pneumococ-
cal diseases compared to those uninfected during a seasonal influenza. The cost-
effectiveness of PCV13 has been previously established. Influenza vaccine (INFv) is 
generally considered as an effective prevention of influenza and is therefore useful 
in alleviating the burden of influenza in reducing morbidities and mortalities. This 
study aims to evaluate the potential cost-effectiveness of joint 13-valent pneumo-
coccal conjugate vaccine (PCV13) and INFv vs influenza vaccine alone for infants and 
elderly. Methods: An age-stratified decision tree model was developed to simulate 
clinical and economic impacts of joint vaccination with PCV13 and INFv in newborns 
and elderly compared to influenza vaccine alone during a seasonal influenza over a 
1-year time horizon. Direct medical costs, epidemiological, demographic parameters 
are Taiwan-specific. Effectiveness of vaccines is based on previous trials adjusted for 
local age-specific stereotype distributions. Herd effect estimates were extrapolated 
from the US post-PCV surveillance data. The study was performed from a payer 
perspective. Current market prices of vaccines were used. One-way and multivari-
ate probabilistic sensitivity analyses were performed to identify influential factors 
to outcomes. Results: Compared to influenza vaccination alone, over 1-year time 
horizon, joint vaccination of PCV13 and INFv is predicted to prevent 386 cases of 
invasive pulmonary diseases, 4,232 cases of all-cause pneumonia, 32,652 cases of 
acute otitis media and 202 deaths (equivalent to 3,131 life years). The universal 
vaccination is expected to save NT$352,593,433 (US$11,753,114) in direct medical 
cost equivalent to NT$947,629 (US$31,587) per life year gained. The results are sen-
sitive to vaccine prices and incidence of influenza. ConClusions: Using WHO-
recommended cost-effectiveness threshold, universal vaccination program with 
PCV13 and INFv appears to be a cost-effective policy in Taiwan.
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group (65%). After 6 months, patients treated with SISEM had substantially higher 
ulcer-free weeks compared to SC (20.0 versus 16.8, respectively). Expected direct 
costs per patient were $2,360 for SISEM and $1,326 for SC. The incremental cost-
effectiveness ratio (ICER) for SISEM was $349 (approximately $50/day), indicating 
that for each $349 paid for SISEM therapy patients gained one additional ulcer-free 
week. ConClusions: SISEM yielded better outcomes at a slightly higher cost in 
patients with mixed A/V and VLUs. SISEM is an effective treatment for wound heal-
ing and should be considered for use in the management of mixed A/V and VLUs.
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objeCtives: To assess the cost-effectiveness of the introduction of the quadriva-
lent HPV vaccine in Argentina. Methods: Using a transmission dynamic model 
developed and published by Elbasha in 2008 we evaluated the routine vaccination 
of 11-year-old girls over a time horizon of 100 years from the perspective of the 
health care system Results: The model showed that the introduction of the vac-
cine will gradually reduce the incidence of cervical cancer, CIN 1/2/3, and genital 
warts related to HPV 6/11/16/18. When compared with non-vaccination, a women 
who completed the three dose scheme will experience a reduction of cervical cancer 
incidence and death, CIN2/3, CIN1 and genital warts of 58,6%, 59,2%, 56,7%, 56,3% 
and 67,3% respectively. Considering a 5% discount rate and a 43,8% of complete 
scheme coverage without heard immunity, the incremental cost-effectiveness ratio 
(ICER) was 795 USD per quality-adjusted life-year (QALY) gained. The additional 
protection against HPV types 6/11 has a great influence in the cost-effectiveness, 
the ICER was almost doubled when not contemplated the protection against HPV 
6/11. The most influential parameters on the scenario analysis were the discount 
rate, the cost of the vaccine and the cost of treatment. However, the vaccine was 
very cost-effective (less than one gross domestic product= 7844 USD) in all the tested 
scenarios. ConClusions: The implementation of routine HPV vaccination with 
the quadrivalent vaccine in 11-year-old girls in Argentina could provide significant 
benefits to public health by reducing cervical cancer incidence and death rates 
and the incidence of CIN 1/2/3 and genital warts, making it a highly cost-effective 
intervention
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objeCtives: The validation of complex economic models against observational 
cohorts tests the accuracy of structural assumptions in models and the relation-
ship between variables and the validity of model outcomes. However, these exer-
cises are seldom conducted and published. The study objectives were to assess 
how well a newly developed economic model for HIV (ARAMIS-DTG) predicts CD4+ 
cell-count changes and AIDS-related outcomes and to explore drivers of eventual 
discrepancies between simulated and observed outcomes. Methods: Clinical out-
comes from ARAMIS-DTG were compared to an observational cohort of patients 
initiating antiretroviral treatment in the British Columbia Centre for Excellence 
(BC-CfE) between 2008 and 2011. Baseline population characteristics and treat-
ment efficacy were modified to reflect the observational cohort in the model, and 
mean changes in CD4+ cell-count and incidence rates of AIDS-related events were 
simulated in ARAMIS-DTG. The impact of relevant ARAMIS parameters on these 
outcomes, such as mortality or virological suppression, was assessed in sensitivity 
analyses. Results: In the base case analysis, the average CD4+ cell-count over five 
years increased from 295 to 682 cells/µL in ARAMIS-DTG and from 303 to 532 cells/
µL in the BC-CfE cohort, reflecting a potential overestimation of adherence in the 
clinical trial setting. However, despite a higher CD4+ cell-count, the incidence of 
AIDS-related events was also higher in ARAMIS: 3.81 vs. 2.84 per 100,000 person-
years, suggesting the higher incidence of AIDS-related events in ARAMIS-DTG was 
mostly attributable to the pre-2005 rates used to inform the model. Sensitivity analy-
ses produced similar results without adjusting ARAMIS-DTG to the BC-CfE cohort 
characteristics. ConClusions: Although results highlight the need for calibrating 
economic models and accounting for factors such as adherence to achieve better 
alignment with real life data, in the particular case of ARAMIS-DTG the differences 
between simulated and observed outcomes did not significantly affect its overall 
cost-effectiveness outcomes.
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objeCtives: Our objective was to evaluate the cost-effectiveness of currently 
recommended pharmacotherapies [response-guided triple therapies with 
pegylated-interferon plus ribavarin (PR) plus boceprevir (BOC) or telaprevir (TVR) or 
simeprevir (SIM) or sofosbuvir (SOF)] for the treatment of newly diagnosed patients 
with genotype 1 chronic hepatitis C virus (HCV) infection, from payer’s perspec-
tive. Methods: A Markov cohort model was developed to simulate the disease 
progression of treatment naïve HCV patients initiating therapy. The model included 
the following outcomes: sustained virologic response (SVR) i.e. absence of detect-
able RNA of virus in blood serum at 12/24 weeks after ending treatment, relapse 
